<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131246">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02062177</url>
  </required_header>
  <id_info>
    <org_study_id>Propofol TCI endoscopy</org_study_id>
    <nct_id>NCT02062177</nct_id>
  </id_info>
  <brief_title>Propofol Administered by Gastroenterologists by Target Controlled Infusion Pump During Endoscopy</brief_title>
  <acronym>Propofol TCI</acronym>
  <official_title>Propofol Administered by Gastroenterologists by Target Controlled Infusion Pump During Endoscopy: a Randomized Double Blind Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Vita-Salute San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università Vita-Salute San Raffaele</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many studies address safety of non-anesthesiologist propofol sedation (NAPS) for
      gastrointestinal endoscopy. Target Controlled Infusion (TCI) is a sophisticated tool for
      providing optimal sedation regimen and avoiding under or oversedation. The objective of the
      study is to compare standard moderate sedation during upper endoscopy and colonoscopy versus
      propofol NAPS.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Endoscopist's satisfaction (Visual Analog Scale) about sedation</measure>
    <time_frame>one day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Visual Analog Scale 0-100 will be used to assess the technical difficulty of examination and the satisfaction with sedation of patient experienced by endoscopist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's satisfaction (Visual Analog Scale) about sedation at the end of procedure</measure>
    <time_frame>one day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>When completely awake, patients will be asked to rate the degree of pain/discomfort and the degree of satisfaction about quality of sedation on a 100 mm visual analog scale (VAS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's satisfaction (Visual Analog Scale) about sedation at 24-48 hours after procedure</measure>
    <time_frame>one day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will be contacted by telephone 24-72 hours after discharge and asked about their satisfaction about the quality of sedation, rated on a verbal rating scale, with 0 corresponding to no satisfaction and 100 to complete satisfaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time (minutes) to dischargeability of patient from endoscopic unit</measure>
    <time_frame>one day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>After endoscopy, patients will be transferred to recovery area and evaluated every 5 minutes until they will be ready to be discharged from the Endoscopy Unit. Recovery will be assessed using the Modified Aldrete Scoring System; patients will be considered fit for discharge with a Modified Aldrete Scoring System score of 18 or more, stable vital signs and without nausea, vomiting, or itching.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>one day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with adverse events (hypotension, bradycardia, hypoxemia,...)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Sedation</condition>
  <condition>Endoscopy</condition>
  <arm_group>
    <arm_group_label>propofol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>midazolam group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>70 patients are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).</description>
    <arm_group_label>propofol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>70 patients in group midazolam are sedated with midazolam 0.04 mg/Kg if aged &lt; 70, 0.03 mg/Kg if aged &gt; 70.</description>
    <arm_group_label>midazolam group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &lt; 18 years

          -  American Society of Anesthesiologists risk I-II

          -  patients undergoing to Gastroscopy or Colonoscopy

        Exclusion Criteria:

          -  significant systemic disease

          -  allergic reactions to any of study drugs

          -  chronic use of opioids or psychiatric disorders

          -  pregnancy

          -  Mallampati score &gt; 2

          -  age &lt; 18 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pier Alberto Testoni, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Vita-Salute San Raffalele University- San Raffaele Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pier Alberto Testoni, Professor</last_name>
    <phone>+39 02.2643.2756</phone>
    <email>testoni.pieralberto@hsr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorella Fanti, Dr</last_name>
      <phone>+39 02.2643.6302</phone>
      <email>lorella.fanti@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Lorella Fanti, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Agostoni, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>February 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università Vita-Salute San Raffaele</investigator_affiliation>
    <investigator_full_name>Testoni Pier Alberto</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
